Skip to content
Ensuring a brighter future for U.S. biotech requires modernizing the Food and Drug Administration (FDA) and addressing challenges from China, according to Kelly Seagraves, […]
BIO expert: Future of biotech depends on competing with China, updating FDA Read More »
Strong intellectual property protections sustain biotechnology innovation by enabling the investment needed to develop new medical breakthroughs. In comments submitted for the 2026 U.S.
BIO’s comments for USTR report highlight global threats to intellectual property Read More »
China is becoming an increasingly influential player in the global biotech market. More than a third of U.S. licensing deals this year have involved
BIG Summit: Seeking opportunities while navigating risks of global trade Read More »
Biotech is a global business, and we’re better for it, said experts at the 2025 Biotechnology Innovation Organization (BIO) International Convention in Boston. International
BIO 2025: The world can’t wait – it needs to collaborate Read More »
A group led by the Biotechnology Innovation Organization (BIO) will recommend new international guidelines for manufacturers of cell and gene therapies (CGT) to support
BIO group to suggest global guidelines for regulating cell and gene therapies Read More »
Given the importance of intellectual property for biotech, the Biotechnology Innovation Organization (BIO) remains vigilant in ensuring IP is protected. In recognition of World
BIO IP expert reviews the current policy landscape Read More »
The BIO Delegation (pictured from left): Tasuku Kitada (Strand Therapeutics), Adam Roach (BeOne Medicines, formerly Beigene), Jacob Becraft (Strand Therapeutics), John F. Crowley (BIO),
BIO’s mission to Tokyo builds on fruitful cooperation Read More »
The world needs regulatory reform and greater R&D investment to enable “moonshot” biotech innovations in food production that can meet our growing food needs,
Nobel and World Food Prize holders: Enable biotech innovation for food Read More »
A dispute panel ruled that Mexico’s planned ban on imports of biotech corn is “not based on relevant scientific principles” and would violate the U.S.-Mexico-Canada
USMCA dispute panel halts Mexico’s ban on biotech corn Read More »
Proposed federal rules on exchange of medical data with China and five other “countries of concern” can protect Americans without obstructing the global flow
Data transfer rules don’t have to hamper biotech innovation, BIO says Read More »
